Jodi Carey

1.5k total citations
11 papers, 220 citations indexed

About

Jodi Carey is a scholar working on Genetics, Pathology and Forensic Medicine and Hematology. According to data from OpenAlex, Jodi Carey has authored 11 papers receiving a total of 220 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Genetics, 6 papers in Pathology and Forensic Medicine and 6 papers in Hematology. Recurrent topics in Jodi Carey's work include Chronic Lymphocytic Leukemia Research (8 papers), Lymphoma Diagnosis and Treatment (6 papers) and Multiple Myeloma Research and Treatments (5 papers). Jodi Carey is often cited by papers focused on Chronic Lymphocytic Leukemia Research (8 papers), Lymphoma Diagnosis and Treatment (6 papers) and Multiple Myeloma Research and Treatments (5 papers). Jodi Carey collaborates with scholars based in United States, Netherlands and Spain. Jodi Carey's co-authors include Astrid McKeown, Steen Lisby, Tadeusz Robak, Ira Gupta, Sebastian Grosicki, Chai‐Ni Chang, Mark‐David Levin, Tahamtan Ahmadi, Jessica Vermeulen and Pieter Sonneveld and has published in prestigious journals such as Journal of Clinical Oncology, Blood and British Journal of Haematology.

In The Last Decade

Jodi Carey

11 papers receiving 213 citations

Peers

Jodi Carey

GENET

PFM

HEMAT

ONCOL

Laura Stampleman United States

Iryna Kryachok Ukraine

Jeffrey P. Sharman United States

Jana Mihályová Czechia

Sean D. Reiff United States

Ranjit Banwait United States

John Hanna United States

JA Burger United States

Juan Garcia‐Talavera Spain

Mark-David Levin Netherlands

Laura Stampleman United States

Jodi Carey

113 ×0.9

GENET

85 ×0.8

PFM

105 ×1.0

HEMAT

94 ×1.1

ONCOL

115 ×1.5

Citations per year, relative to Jodi Carey Jodi Carey (= 1×) peers Laura Stampleman

Countries citing papers authored by Jodi Carey

Since Specialization

Citations

This map shows the geographic impact of Jodi Carey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jodi Carey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jodi Carey more than expected).

Fields of papers citing papers by Jodi Carey

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jodi Carey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jodi Carey. The network helps show where Jodi Carey may publish in the future.

Co-authorship network of co-authors of Jodi Carey

This figure shows the co-authorship network connecting the top 25 collaborators of Jodi Carey. A scholar is included among the top collaborators of Jodi Carey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jodi Carey. Jodi Carey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Spencer, Andrew, Philippe Moreau, María‐Victoria Mateos, et al.. (2023). Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUX. Blood Advances. 8(2). 388–398. 5 indexed citations

Spencer, Andrew, Philippe Moreau, María‐Victoria Mateos, et al.. (2022). Daratumumab (DARA) in combination with bortezomib plus dexamethasone (D-Vd) or lenalidomide plus dexamethasone (D-Rd) in relapsed or refractory multiple myeloma (RRMM): Subgroup analysis of the phase 3 CASTOR and POLLUX studies in patients (pts) with early or late relapse after initial therapy.. Journal of Clinical Oncology. 40(16_suppl). 8052–8052. 4 indexed citations

Sonneveld, Pieter, Katja Weisel, Ajay K. Nooka, et al.. (2022). P04: DARATUMUMAB PLUS BORTEZOMIB AND DEXAMETHASONE VERSUS BORTEZOMIB AND DEXAMETHASONE ALONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: OVERALL SURVIVAL RESULTS FROM THE PHASE 3 CASTOR TRIAL. HemaSphere. 6. 12–12. 3 indexed citations

Sonneveld, Pieter, Asher Chanan‐Khan, Katja Weisel, et al.. (2022). Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial. Journal of Clinical Oncology. 41(8). 1600–1609. 63 indexed citations

Balasubramanian, Sriram, Songbai Wang, Christopher Major, et al.. (2021). Comparison of immunohistochemistry and gene expression profiling subtyping for diffuse large B‐cell lymphoma in the phase III clinical trial of R‐CHOP ± ibrutinib. British Journal of Haematology. 194(1). 83–91. 5 indexed citations

Zweegman, Sonja, Saad Z. Usmani, Katherine Chastain, et al.. (2019). Bortezomib, lenalidomide, and dexamethasone (VRd) ± daratumumab (DARA) in patients (pts) with newly diagnosed multiple myeloma (NDMM) for whom transplant is not planned as initial therapy: A multicenter, randomized, phase III study (CEPHEUS).. Journal of Clinical Oncology. 37(15_suppl). TPS8056–TPS8056. 26 indexed citations

Younes, Anas, Laurie H. Sehn, Peter Johnson, et al.. (2018). A Global, Randomized, Placebo-Controlled, Phase 3 Study of Ibrutinib Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (RCHOP) in Patients with Previously Untreated Non-Germinal Center B-Cell-like (GCB) Diffuse Large B-Cell Lymphoma (DLBCL). Blood. 132(Supplement 1). 784–784. 13 indexed citations

Robak, Tadeusz, Krzysztof Warzocha, Govind Babu, et al.. (2016). Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial. Leukemia & lymphoma. 58(5). 1084–1093. 39 indexed citations

Robak, Tadeusz, Sebastian Grosicki, Krzysztof Warzocha, et al.. (2015). Ofatumumab (O) in combination with fludarabine (F) and cyclophosphamide (C) (OFC) vs. FC in patients with relapsed chronic lymphocytic leukaemia (CLL): results of the phase III study complement 2. Haematologica. 100. 3 indexed citations

10.

Jewell, Roxanne C., Kevin Laubscher, Eric Lewis, et al.. (2014). Assessment of the effect of ofatumumab on cardiac repolarization. The Journal of Clinical Pharmacology. 55(1). 114–121. 1 indexed citations

11.

Hillmen, Peter, Tadeusz Robak, Ann Janssens, et al.. (2013). Ofatumumab + Chlorambucil Versus Chlorambucil Alone In Patients With Untreated Chronic Lymphocytic Leukemia (CLL): Results Of The Phase III Study Complement 1 (OMB110911). Blood. 122(21). 528–528. 58 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact